A lipoprotein a test measures a cholesterol-carrying particle that almost never appears on a routine cholesterol panel, yet carries an inherited cardiovascular risk that diet and exercise barely touch. Written Lp(a) and often said out loud as “L-P-little-a,” this particle looks like LDL cholesterol with an extra protein tail attached, and that tail changes everything about how it behaves in your arteries. Roughly one in five people worldwide carries a level high enough to matter, and most of them have never been tested. In this article you will learn what Lp(a) actually is, why your level is set mostly before birth, how to read a result reported in nmol/L or mg/dL, who genuinely needs the test, what an elevated number means for your heart and your aortic valve, and which treatments move the number today versus which ones are still being studied.
What is lipoprotein(a) and how does it differ from LDL cholesterol?
Lipoprotein(a) is a particle made by your liver that carries cholesterol through the bloodstream. Structurally it starts out as an LDL particle: a core of fat and cholesterol wrapped in a shell, with a large protein called apolipoprotein B on the outside. What makes it distinct is a second protein, apolipoprotein(a) or apo(a), stitched onto that shell. The result is an LDL-like particle wearing an extra appendage that no other lipoprotein carries.
The apo(a) tail that changes the particle’s behavior
Apo(a) closely resembles plasminogen, a protein your body uses to dissolve blood clots. Because the two look alike, Lp(a) can interfere with normal clot breakdown while simultaneously delivering cholesterol into artery walls. The particle is also unusually good at carrying oxidized fats, which provoke inflammation in the vessel lining. In practical terms, one particle contributes to three separate problems at once: plaque buildup, clot formation, and inflammation. That triple action is why Lp(a) is treated as its own risk factor rather than a footnote to LDL. If you want the fundamentals of the better-known particle first, start with our LDL cholesterol blood level guide.
Why Lp(a) is missing from your standard cholesterol panel
A standard lipid panel reports total cholesterol, LDL, HDL, and triglycerides. None of those numbers reveal how much of your circulating cholesterol travels on Lp(a) particles specifically. Someone can have an entirely reassuring panel and still carry a high Lp(a) level, which is exactly the scenario that catches people off guard after a heart attack in their forties. To see what the routine workup does and does not cover, review our lipid panel results guide. The Lp(a) test has to be ordered separately, by name.
Why your lipoprotein(a) level is written into your genes
The amount of Lp(a) in your blood is controlled almost entirely by the LPA gene, which you inherit from your parents. That gene comes in many versions, and the version you carry determines how much apo(a) your liver produces and therefore how many Lp(a) particles circulate. According to the National Heart, Lung, and Blood Institute, Lp(a) is more heritable than blood pressure, diabetes, or body weight, and is likely the single most common inherited driver of cardiovascular risk.
One measurement, usually for life
Because the number is genetically fixed, it stays remarkably stable from childhood onward. Your level at twenty-five will look much like your level at sixty. This is why a growing number of cardiology societies recommend measuring Lp(a) once in every adult’s lifetime rather than tracking it annually the way you would track a total cholesterol result. A repeat test becomes useful only in narrow situations: a result that sat close to a decision threshold, a change in laboratory method, or an illness that may have temporarily distorted the reading.
What genuinely does not move the number
Cutting saturated fat, losing weight, running more, or taking a statin will each improve your overall cardiovascular picture, and every one of them is worth doing. None of them meaningfully lowers Lp(a). A handful of situations do nudge it: pregnancy, kidney disease, an underactive thyroid, and acute inflammation can all raise a reading temporarily, while liver disease and some hormone therapies can lower it. If your thyroid status is uncertain, our TSH blood test results guide explains how that gets checked. These influences are modest compared with genetics, but they are a reason to avoid testing during pregnancy or an acute illness.
How to read your lipoprotein(a) result: nmol/L versus mg/dL
Lp(a) is reported in one of two ways, and the difference matters more than it does for most lab values. Laboratories using nmol/L count the number of particles. Laboratories using mg/dL weigh the mass of Lp(a) material. Because apo(a) varies enormously in size from person to person, two people can carry the same particle count and very different masses. There is no reliable conversion factor between the units, so a result in one unit should never be mentally translated into the other.
Particle counting in nmol/L is now the preferred method, since it is not distorted by apo(a) size. When you receive a result, check which unit your laboratory used before comparing it with any threshold you read online.
| Interpretation band | Mass units (mg/dL) | What it generally suggests |
|---|---|---|
| Desirable | Under 30 | No added risk attributable to Lp(a) |
| Borderline | About 14 to 30 | Worth noting alongside your other risk factors |
| High | About 31 to 50 | Meaningful added cardiovascular risk |
| Very high | Above 50 | Strongest signal; prompts family screening |
| Particle count equivalent | Reported in nmol/L | Levels above roughly 100 nmol/L are considered elevated |
Why your number is a risk marker, not a verdict
An elevated Lp(a) raises the probability of a cardiovascular event over a lifetime. It does not predict that one will happen. Cardiologists at the National Heart, Lung, and Blood Institute make this point plainly: an elevated level does not mean you are going to have an event. It means the rest of your risk picture deserves closer attention than it otherwise would.
Who should be tested for lipoprotein(a)?
Many specialists now argue for universal one-time screening in adults. Until that becomes standard practice everywhere, testing is clearly warranted if any of the following apply to you.
- A parent, sibling, or child developed heart disease, a heart attack, or a stroke early in life, generally before 55 in men or 65 in women.
- You have been diagnosed with familial hypercholesterolemia, an inherited condition that keeps LDL cholesterol very high from birth.
- A close relative already has a documented high Lp(a) level.
- You have developed coronary artery disease or aortic valve narrowing despite an unremarkable cholesterol panel.
- Your LDL stays stubbornly high on treatment, or you have had repeated cardiac events despite good control of your other risk factors.
- You have calcific aortic valve stenosis, particularly at a younger age than expected.
The test itself is a simple blood draw. Fasting is generally not required, since Lp(a) does not respond to a recent meal the way triglycerides do. If your clinician has asked you to fast for a combined panel, that instruction relates to the other markers on the order; our triglycerides blood level guide explains why those numbers are meal-sensitive.
When to see a doctor
Book an appointment to discuss testing if premature heart disease runs in your family, if you have been told you have familial hypercholesterolemia, or if a relative has been found to have a high Lp(a) level. Seek urgent care instead of scheduling a test if you have chest pressure, sudden shortness of breath, one-sided weakness, or slurred speech. Those symptoms need immediate evaluation regardless of any laboratory value.
What a high lipoprotein(a) means for your arteries and your aortic valve
Elevated Lp(a) is causally linked to two distinct problems, and the second one surprises most people.
Atherosclerosis, heart attack, and stroke
Lp(a) particles deposit cholesterol in artery walls and promote the inflammation that destabilizes plaque, while the apo(a) tail hampers the body’s ability to break down clots. The combination raises the likelihood of coronary artery disease, heart attack, ischemic stroke, and peripheral artery disease, and it does so independently of your LDL number. Inflammation markers can add context to that picture; our CRP blood test results guide covers the most widely used one.
Calcific aortic valve stenosis
The aortic valve is the door between your heart’s main pumping chamber and the rest of your body. Lp(a) accumulates in valve tissue and drives calcium deposition there, gradually stiffening the leaflets so the door no longer opens fully. This narrowing, called aortic stenosis, eventually causes breathlessness, chest tightness, or fainting on exertion. Lp(a) is one of the few known causal risk factors for it, which is why an unexplained valve finding on an echocardiogram is a reasonable trigger for testing.
What can and cannot lower lipoprotein(a) today
This is the part of the conversation that frustrates patients most, so it is worth being precise about what each option actually does.
| Approach | Effect on Lp(a) | Status |
|---|---|---|
| Diet, exercise, weight loss | Essentially none | Still essential for overall heart risk |
| Statins | None; they lower LDL, not Lp(a) | Widely used for the rest of the lipid picture |
| PCSK9 inhibitors | Partial reduction, roughly a fifth to a third | Approved, prescribed mainly for LDL lowering |
| Lipoprotein apheresis | Large reduction per session, then rebound | Reserved for severe, refractory cases |
| RNA-based Lp(a) therapies | Very large reduction in early studies | Investigational; outcome trials still running |
The treatments that exist now
Statins remain the backbone of lipid management, but they do not lower Lp(a) and may nudge it slightly upward in some people. That is not a reason to stop them: their benefit comes from LDL reduction, which still matters enormously when Lp(a) is high. PCSK9 inhibitors, injectable drugs that help the liver clear LDL, lower Lp(a) partially as a side effect. Lipoprotein apheresis filters apoB-containing particles directly out of the blood during a session lasting a few hours, repeated weekly or every other week; in the United States it is reserved for severe familial hypercholesterolemia and similarly refractory situations. To understand the apoB particle count that ties these approaches together, see our apolipoprotein B test results guide.
The treatments still in trials
A new class of drugs silences the LPA gene message inside liver cells so that far less apo(a) is made. These RNA-based agents produce dramatic reductions in Lp(a) levels in published studies. What nobody can confirm yet is whether lowering the number translates into fewer heart attacks and strokes; large outcome trials designed to answer exactly that question are still under way. No medicine is currently approved with the specific purpose of lowering Lp(a).
What to do if your lipoprotein(a) result is high
A high number is not something you can fix directly today, but it is genuinely actionable in two ways.
Tighten every risk factor you can control
Because Lp(a) adds risk on top of everything else, the practical response is to shrink everything else. That means aggressive LDL management with your clinician, blood pressure kept in range, blood sugar under control, complete avoidance of tobacco, regular activity, and attention to sleep and stress. If diabetes or prediabetes is part of your picture, our HbA1c test results guide explains how long-term glucose control is measured. Homocysteine is sometimes checked alongside these markers; see our homocysteine blood level guide for context. Managing the rest of the picture is covered more broadly in our high cholesterol causes and treatments guide.
Tell your relatives
Because the trait is inherited, a high result in you means your parents, siblings, and children each have a meaningful chance of carrying it too. Testing relatives after an index case is called cascade screening, and it is one of the highest-yield things you can do with the information. A single blood draw can identify family members who would otherwise learn about their risk only after an event. Protective markers are worth understanding in the same conversation; our HDL cholesterol level guide covers the other side of the lipid balance.
Latest scientific advances
Research on Lp(a) has moved quickly over the last two years, mostly in the direction of treatment. Here is what recent work has added, in plain terms.
A 2026 review of the therapeutic landscape from a McGill University team described a pipeline that now includes injectable gene-silencing drugs, an oral tablet that blocks the assembly of the Lp(a) particle, and early laboratory work using gene editing. The same review noted that one-time Lp(a) screening is increasingly recommended, which creates an awkward gap: doctors can now identify the risk long before they can treat it directly. What this means for you is that being tested still has value even without a targeted drug, because it changes how intensively everything else gets managed.
A 2026 systematic review and network meta-analysis — a study that pools many trials and compares treatments that were never tested head to head — examined nine randomized trials of Lp(a)-targeted drugs. All of the agents studied lowered Lp(a) substantially, and several also improved LDL cholesterol and apolipoprotein B. Injection-site reactions were the main tolerability issue. What this means for you is that the biology clearly works; the open question is whether the falling number produces fewer heart attacks, which these trials were not designed to answer.
A separate 2026 network meta-analysis compared the emerging Lp(a) drugs against PCSK9 inhibitors, the injectable cholesterol drugs already on pharmacy shelves. The newer agents lowered Lp(a) far more, while PCSK9 inhibitors lowered LDL cholesterol more. The authors were careful to flag that the trials varied a great deal in design and that confidence in several comparisons is low. What this means for you is that today’s approved drugs remain LDL tools that happen to trim Lp(a) a little, and the findings are still preliminary and need confirmation in outcome trials.
Finally, a 2026 review of lipoprotein apheresis — the procedure that filters cholesterol-carrying particles out of the blood — described more than a decade of registry follow-up showing consistent reductions in serious cardiovascular events, though never in a randomized trial. The authors expect apheresis to keep a role in Lp(a)-driven disease specifically until the RNA-based drugs prove they reduce events. What this means for you is that a demanding but established option exists for the small group with severe, treatment-resistant disease.
Glossary of key terms
| Term | Definition |
|---|---|
| Lipoprotein(a), Lp(a) | An LDL-like particle carrying an extra protein called apo(a). Its concentration is set mainly by inheritance. |
| Apolipoprotein(a), apo(a) | The distinctive protein attached to an Lp(a) particle. Its size varies widely between people, which is why particle counting is preferred. |
| Apolipoprotein B, apoB | The structural protein found on LDL and Lp(a) particles. One apoB marks one potentially artery-damaging particle. |
| LPA gene | The inherited gene that determines how much apo(a) your liver produces, and therefore your Lp(a) level. |
| nmol/L | Nanomoles per liter, a unit that counts Lp(a) particles. Now the preferred way to report the test. |
| mg/dL | Milligrams per deciliter, a unit that weighs Lp(a) mass. It cannot be converted reliably into nmol/L. |
| Familial hypercholesterolemia | An inherited condition causing very high LDL cholesterol from birth and early cardiovascular disease. |
| Aortic stenosis | Narrowing of the aortic valve, often from calcium buildup, which restricts blood leaving the heart. |
| Cascade screening | Testing the close relatives of someone found to carry an inherited risk factor. |
| Lipoprotein apheresis | A procedure that filters cholesterol-carrying particles out of the blood, used in severe cases. |
Frequently asked questions
What is a normal lipoprotein a level?
In mass units, a level under 30 mg/dL is generally considered desirable, with results above 50 mg/dL treated as clearly elevated. When the laboratory counts particles instead, results above roughly 100 nmol/L are considered elevated. Reference ranges differ between laboratories and between assay methods, so read your result against the range printed on your own report rather than a number found online. Because the two unit systems measure genuinely different things, a value in mg/dL cannot be converted into nmol/L with any reliability.
Do I need to fast before a lipoprotein a test?
Usually not. Lp(a) levels do not respond much to a recent meal, so most laboratories accept a non-fasting sample. You may still be asked to fast if the Lp(a) test is bundled with a full lipid panel, since triglycerides do rise after eating. Follow whatever instruction your clinician or laboratory gives you, and mention any recent illness, pregnancy, or thyroid problem, because those situations can shift the result temporarily.
How often should lipoprotein a be tested?
For most people, once is enough. The level is genetically determined and stays stable across adult life, so repeat testing rarely adds information. A second measurement can be reasonable if the first result sat very close to a decision threshold, if it was drawn during pregnancy or an acute illness, or if your laboratory has changed assay methods. Discuss any repeat with the clinician who ordered the original test.
Can diet or exercise lower lipoprotein a?
Not meaningfully. Unlike LDL cholesterol or triglycerides, Lp(a) barely responds to changes in what you eat or how much you move. That does not make those changes pointless. Because elevated Lp(a) adds risk on top of your other risk factors, improving diet, activity, weight, blood pressure, and blood sugar reduces the total burden your arteries face, which is the most effective thing available to you today.
Does a high lipoprotein a mean I will have a heart attack?
No. An elevated level raises the statistical likelihood of cardiovascular disease over a lifetime; it does not determine what will happen to any individual. Many people with high Lp(a) never experience an event, particularly when their other risk factors are well managed. The right way to read the number is as a signal to treat everything else more carefully, and to make sure close relatives get tested.
Should my children be tested for lipoprotein a?
If your own level is high, testing first-degree relatives including children is often recommended, because each has a substantial chance of carrying the same inherited pattern. The right age to test depends on family history and on your pediatrician’s judgment, and it is usually discussed alongside screening for familial hypercholesterolemia. Raise the question with your child’s clinician rather than arranging a test independently.
Sources
- MedlinePlus, National Library of Medicine — Lipoprotein (a) Blood Test — MedlinePlus Medical Test, reviewed 2025 — medlineplus.gov
- National Heart, Lung, and Blood Institute — Lipoprotein(a): What to Know About Elevated Levels — NHLBI, 2024 — nhlbi.nih.gov
- Cleveland Clinic — Who Needs a Test for Lipoprotein (a)? — Cleveland Clinic Health Library, 2025 — my.clevelandclinic.org
- Centers for Disease Control and Prevention — About Cholesterol — CDC, 2024 — cdc.gov
- Anchouche K, Koran N, Thanassoulis G — Old and New Lines of Therapy Targeting Lipoprotein(a) — Current Atherosclerosis Reports, 2026 — doi.org/10.1007/s11883-026-01419-x
- Hu J, Wang J, Zhang H, Jiang Y, Deng L, Long E, Liu S — Efficacy and Safety of Lipoprotein(a)-Targeted Therapeutics: A Systematic Review and Network Meta-Analysis — Frontiers in Cardiovascular Medicine, 2026 — doi.org/10.3389/fcvm.2026.1758366
- Abu Zayed J, Al-Awamleh NA, Hamad M, Hdaib MIM, Ayesh H — Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials — Diabetes, Obesity and Metabolism, 2026 — doi.org/10.1111/dom.70944
- Nadim M, Akgun Y — Lipoprotein Apheresis: From Familial Hypercholesterolemia and Elevated Lipoprotein(a) to Emerging Roles in Peripheral Arterial and Renal Disease — Transfusion and Apheresis Science, 2026 — doi.org/10.1016/j.transci.2026.104483
Further reading
- Compare the protein that travels with protective cholesterol by reading our apolipoprotein A1 level guide.
- Explore the low-grade inflammation that quietly accompanies arterial disease in our hs-CRP silent inflammation guide.
- Learn how clinicians detect strain on a struggling heart with our NT-proBNP test results guide.
- Check the marker that signals injury to heart muscle by reading our troponin blood test results guide.
- Track the blood sugar value that shapes long-term cardiovascular risk with our fasting glucose test results guide.
Understand your lab results with BloodSense
An Lp(a) result rarely arrives alone. It usually sits on a report next to LDL cholesterol, HDL cholesterol, triglycerides, and apolipoprotein B, and the meaning comes from how those numbers fit together rather than from any single line. BloodSense reads your report and explains each value in plain language, including which markers move with lifestyle and which, like Lp(a), do not. It helps you understand what you are looking at and prepare better questions for your clinician; it does not diagnose you and it does not replace medical care.
